, Singapore

Why SPH's foray to healthcare wouldn't be a game-changer

Orange Valley Healthcare's yearly earnings are too small.

Singapore Press Holdings (SPH)'s revenue stream diversification to offset loss might fall short of expectations in the near term.

According to UOB Kay Hian, SPH's acquisition of Orange Valley Healthcare is unlikely to be an earnings game-changer.

Analyst Foo Zhi Wei said Orange Valley Healthcare's yearly earnings of $5m to $6m remain too small to offset SPH's core earnings decline of $18m.

The analyst added any expansion will require a near tripling of current beds to contribute meaningful earnings.

"With SPH’s core earnings expected to decline by another S$18m in FY18, earnings from OVH will have to grow by as much to arrest the decline. Making simplified assumptions of $104/day per bed and net margin of 17%, OVH will have to increase its current bed capacity from about 900 beds to over 2,800 to achieve net profit of $18m," the analyst explained.
 

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
Shipping & Marine
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare